Adipotide is an experimental peptidomimetic, a lab-made molecule that behaves like a peptide, designed to cut off the blood supply of fat tissue. It is not FDA-approved, and its only registered human study ended early after enrolling four people.
Adipotide has two working parts. One part homes in on prohibitin, a protein found on the surface of the blood vessel cells that supply white fat. The other part is designed to trigger programmed cell death (apoptosis) in those vessel cells. With its blood supply reduced, the fat tissue is reabsorbed by the body.
Adipotide came from the laboratory of Wadih Arap and Renata Pasqualini, then at the University of Texas MD Anderson Cancer Center. According to MD Anderson, obese mice lost about 30% of their body weight in earlier studies.
In November 2011, the team reported in Science Translational Medicine that obese rhesus monkeys lost an average of about 11% of their body weight after four weeks of daily treatment, with a 27% drop in abdominal fat on MRI scans. The treated animals also had effects on kidney function, which the researchers described as predictable and reversible.
MD Anderson then registered a first-in-human phase 1 study in men with metastatic prostate cancer and obesity, listing the drug as Prohibitin-TP01. It began in 2012, enrolled four patients and was terminated at the principal investigator's request. No results have been posted on ClinicalTrials.gov, and no trial of adipotide for weight management in people has been registered there.
According to MD Anderson, researchers involved in the work held equity in companies formed to develop the compound.
Current status: Investigational – not FDA-approved.
An investigational drug is one that has been studied in people under FDA oversight but has not been approved. Adipotide has not completed any phase of clinical testing, and no active trials were listed on ClinicalTrials.gov as of September 2026. It does not appear in any category of the FDA's 503A nomination lists (as updated May 14, 2026) and is not on the 503A bulks list, so it does not meet the conditions for 503A compounding.
It is also not a dietary supplement. Products labeled "for research purposes only" or "not for human consumption" are not approved medicines, and the FDA has not reviewed their contents, purity or quality.
The safety of adipotide in people has not been established. In the monkey study, effects on the kidneys were the main side effect reported. The FDA has not published a safety assessment of adipotide.
Adipotide is not named on the World Anti-Doping Agency (WADA) 2026 Prohibited List. The list's S0 class covers any pharmacological substance not addressed elsewhere on the list that has no current approval by any government health authority for human therapeutic use. Athletes should confirm the status of any substance with their anti-doping organization.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We do not supply, prepare or distribute adipotide in any form, and nothing on this page should be read as an offer.
If you have questions about weight management, talk to a licensed healthcare provider, who can discuss FDA-approved options.
See the full list of compound profiles in the Peptide Guide. Related profiles: AOD-9604 and MOTS-c. For approved options, read how semaglutide and tirzepatide are regulated or our overview of peptides for weight loss.